John Libbey Eurotext

European Journal of Dermatology


Portuguese recommendations for the treatment of psoriasis with biologic therapy Volume 30, numéro 6, November-December 2020


  • Figure 1


Paulo Filipe On Behalf of the Portuguese Psoriasis Group of the Portuguese Society of Dermatology and Venereology 12 13 14
1 Department of Dermatology, Centro Hospitalar Universitário do Porto, PortoPortugal
2 Instituto de Ciências Biomédicas Abel Salazar, University of Porto, PortoPortugal
3 Department of Dermatology, Hospital Lusíadas, Lisboa,Portugal
4 Department of Dermatology, Centro Hospitalar Universitário de Lisboa Central, LisboaPortugal
5 CEDOC, NOVA Medical School, Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, LisboaPortugal
6 Hospital da Luz, LisboaPortugal
7 Psoriasis Unit, Hospital CUF Descobertas, LisboaPortugal
8 Department of Dermatology, Centro Hospitalar VN Gaia/Espinho, VN Gaia, Portugal
9 Escola de Medicina, University of Minho, BragaPortugal
10 Private practice, PortoPortugal
11 Private practice, LisboaPortugal
12 Department of Dermatology, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, LisboaPortugal
13 Faculty of Medicine, University of Lisboa, LisboaPortugal
14 Dermatology Research Unit, iMM João Lobo Antunes, University of Lisboa, LisboaPortugal
* Reprints

Psoriasis is a highly prevalent chronic, inflammatory multisystem disease with a considerable impact on patients’ quality of life and the healthcare system. This report presents the recommendations developed by the Portuguese Psoriasis Group of the Portuguese Society of Dermatology and Venereology that address several clinical questions arising during the management and care of psoriasis with biologic therapy, based on the available evidence. The recommendations were generated following thorough evaluation of existing guidelines on the treatment of psoriasis, publications concerning new biologic treatments that have not yet been considered in existing guidelines, as well as expert-based recommendations. Considerations regarding the severity of psoriasis, indications for initiating biologic therapy, parameters to be considered in treatment choice (in particular, treatment goals), as well as recommendations for using and monitoring therapy and screening programmes are also included.